Pancreatic Adenocarcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 36 expanded access programs, clinical trials, and compassionate use pathways listed for Pancreatic Adenocarcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with pancreatic adenocarcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 11 programs are currently active or recruiting, with the remaining 25 in other lifecycle stages. Sponsors actively running programs in this area include Revolution Medicines, Inc., Immuneering Corporation, Mirati Therapeutics Inc., Actuate Therapeutics Inc., Alliance for Clinical Trials in Oncology, and others.
By recruiting status
Snapshot of where every Pancreatic Adenocarcinoma program currently sits in its lifecycle.
- Active / Recruiting11
- Inactive25
Top sponsors
Organisations running the most Pancreatic Adenocarcinoma programs in the directory.
- Revolution Medicines, Inc.3 programs
- Immuneering Corporation2 programs
- Mirati Therapeutics Inc.2 programs
- Actuate Therapeutics Inc.1 program
- Alliance for Clinical Trials in Oncology1 program
- Apollo Therapeutics Ltd1 program
- Ashish Manne1 program
- Astellas Pharma Global Development, Inc.1 program
- Baylor Research Institute1 program
- Bristol-Myers Squibb1 program
Pancreatic Adenocarcinoma programs (36)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 9-ING-41 for Patients with Advanced Cancers — Actuate Therapeutics Inc.
- Study on ASP546C for Adults with Gastroesophageal, Pancreatic, and Other Solid Tumors — Astellas Pharma Global Development, Inc.
- Study on Atebimetinib and Modified Chemotherapy for First-Line Treatment of Metastatic Pancreatic Cancer — Immuneering Corporation
- Study on Treating Basal-like Pancreatic Cancer with Gemcitabine, Erlotinib, and Nab-paclitaxel — UNC Lineberger Comprehensive Cancer Center
- Expanded Access Program for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer — Revolution Medicines, Inc.
- Study on Combining Radiation Therapy with Durvalumab for Pancreatic Cancer — Memorial Sloan Kettering Cancer Center
- Study on Daraxonrasib and Daraxonrasib with Chemotherapy as First Treatment for Metastatic Pancreatic Cancer — Revolution Medicines, Inc.
- Study of DECOY20 with or Without Tislelizumab in Patients with Advanced Solid Tumors — Indaptus Therapeutics, Inc
- Study of LP-184 for Patients with Advanced Solid Tumors — Lantern Pharma Inc.
- Study on Zoldonrasib with Chemotherapy vs. Placebo with Chemotherapy for First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Cancer — Revolution Medicines, Inc.
- Study on GTAEXS617 for Adults with Advanced Solid Tumors — Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Study on TC-510 Cell Therapy for Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Study on IMM-1-104 for Patients with Previously Treated Advanced or Metastatic Solid Tumors with RAS Mutation — Immuneering Corporation
- Study on the Safety and Effectiveness of CTX131 for Adults with Returning or Hard-to-Treat Solid Tumors — CRISPR Therapeutics AG
- Study on BMS-986340 Alone and with Nivolumab or Docetaxel for Advanced Solid Tumors — Bristol-Myers Squibb
- Study on NovoTTF-200T(P) with Gemcitabine and Nab-Paclitaxel for Treating Resectable Pancreatic Cancer — Ashish Manne
- Study on APL-5125 for Adults with Advanced Solid Tumors — Apollo Therapeutics Ltd
- Study on Atezolizumab and Tivozanib for Treating Certain Hard-to-Treat Cancers — University of Florida
- Study on Chemotherapy and Anakinra for Patients with Pancreatic Cancer — Baylor Research Institute
- Evaluating Novel Therapies in ctDNA Positive GI Cancers — Georgetown University
- Study on FOLFIRINOX, 9-ING-41, and Losartan for Pancreatic Cancer — Colin D. Weekes, M.D., PhD
- Study on Using Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Spread to the Liver — Spectrum Health Hospitals
- Study on Radiation and Chemotherapy with or without Zoledronic Acid for Locally Advanced Pancreatic Cancer — University of Nebraska
- Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma — University of Louisville
- Study on ESK981 for Patients with Certain Types of Solid Tumors — University of Michigan Rogel Cancer Center
- Study on Nab-Paclitaxel, Cisplatin, Gemcitabine, and Tumor Treatment Fields for Metastatic Pancreatic Cancer — Mayo Clinic
- NeoOPTIMIZE: Early Switching of Chemotherapy Before Surgery for Treating Pancreatic Cancer — OHSU Knight Cancer Institute
- Study on Panitumumab-IRDye800 for Patients with Pancreatic Cancer Undergoing Surgery — Eben Rosenthal
- Study on Lurbinectedin and Irinotecan for Patients with Certain Advanced Cancers — PharmaMar
- Phase 1/2 Study of MRTX1719 for Solid Tumors with MTAP Gene Deletion — Mirati Therapeutics Inc.
- Pre-operative Treatment for Patients with Untreated Pancreatic Cancer — HonorHealth Research Institute
- Study on Combining Stereotactic Body Radiotherapy with FAK and RAF/MEK Inhibitors for Advanced Pancreatic Cancer — Washington University School of Medicine
- Study on MRTX1133 for Patients with Advanced Solid Tumors with a KRAS G12D Mutation — Mirati Therapeutics Inc.
- Study on Nab-Paclitaxel and Gemcitabine with or without VCN-01 for Patients with Metastatic Pancreatic Cancer — Theriva Biologics SL
- Study on Adding Pembrolizumab to Olaparib for Treating Pancreatic Cancer with Inherited BRCA Mutations — National Cancer Institute (NCI)
- The PLATINUM Trial: Optimizing Chemotherapy for Second-Line Treatment of Metastatic Pancreatic Cancer with BRCA1/2 or PALB2 Mutations — Alliance for Clinical Trials in Oncology
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Pancreatic Adenocarcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.